Barriers to the development of a screening tool include: the low prevalence of ovarian cancer in the general population, the inaccessibility of the ovaries to direct evaluation, non-specificity of known tumor markers (such as CA125) [1], and the absence of known risk factors (such as high-risk genetic mutations) for the majority of patients. This evidence concerns the gene MUC16 and ovarian cancer.